Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)

v3.21.2
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2021
USD ($)
May 31, 2019
USD ($)
Aug. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
Sep. 30, 2019
USD ($)
Jul. 31, 2018
USD ($)
Program
Aug. 31, 2017
Program
Jun. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
2019 EMD Serono Supply Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                 $ 1,000,000.0 $ 1,000,000.0 $ 1,000,000.0
BMS Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of programs advancing through preclinical development | Program               4      
Contingent payments   $ 275,000,000.0                  
Deferred revenue                 0 0 0
2018 BMS Master Services Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                 1,200,000 1,200,000 1,200,000
2018 Merck Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                 6,100,000 6,100,000 18,500,000
Milestone payment receivable upon initiation of IND enabling toxicology study                 15,000,000.0 15,000,000.0  
Recognition of up front payment                 60,600,000 60,600,000  
Incremental revenue recognized                   9,100,000  
2018 Merck Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Incremental transaction price allocation resulted in additional revenue recognized                   100,000  
Contingent payment received                 15,000,000.0    
2018 Merck Agreement | Merck Sharp & Dohme Corp                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of research programs | Program             3        
Initial transaction price             $ 60,000,000.0        
Upfront payment received                   60,000,000.0  
Revenue recognition aggregate contingent payments eligible to receive                   $ 500,000,000  
Milestone method revenue recognition description                   If one or more products from each of the target programs are developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate milestone payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration.  
2018 Merck Agreement | Merck Sharp & Dohme Corp | Accounting Standards Update 2014-09                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Total interest of unearned revenue                 7,400,000 $ 7,400,000  
First Cytokine-Derivative Program | Merck Sharp & Dohme Corp                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received       $ 5,000,000.0              
Extended research term       1 year              
Transaction price $ 65,000,000.0     $ 65,000,000.0 $ 60,000,000.0       80,000,000.0    
Constrained variable consideration         $ 5,000,000.0       15,000,000.0    
Revenue reallocated property rights                   9,400,000  
Incremental revenue recognized reallocated target programs                   $ 1,600,000  
Estimated service period                   3 years  
Incremental revenue recognized                   $ 3,200,000  
Adjustments to transaction price                   9,100,000  
Cumulative catch-up in revenue                 14,000,000.0    
2020 Merck Master Services Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                 0 0 0
MDA Agreement | EMD Serono                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue                 0 0 $ 0
Contingent payment received           $ 1,500,000     $ 2,000,000.0    
Maximum amount eligible to receive for each product developed                   $ 52,500,000  
Milestone payment received     $ 1,000,000.0